Clinical Trial: The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Type 2 Diabetes
Study Type: INTERVENTIONAL
Official Title: The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
Brief Summary:
This study explores the long-term effects of dapagliflozin and empagliflozin on CYP8B1 gene expression and a range of metabolic, oxidative, and inflammatory biomarkers in obese patients with Type 2 Diabetes Mellitus (T2DM).Over a 6-month period, participants are assigned to three treatment arms: metformin (control), dapagliflozin, and empagliflozin.The study aims to determine how these medications influence bile acid metabolism, oxidative stress, leptin, GLP-1, IL-10, and IFN-?, providing insight into the broader…
Read more